Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(817/week)
    • Manufacturing(417/week)
    • Energy(348/week)
    • Technology(776/week)
    • Other Manufacturing(285/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Ramucirumab

May 29, 2020
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Feb 26, 2020
FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Jan 25, 2020
Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)
Dec 13, 2019
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Oct 07, 2019
Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology
May 15, 2019
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
May 13, 2019
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
Feb 25, 2019
FDA Approves Taiho Oncology's LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Jan 18, 2019
Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients
Jan 01, 2019
Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer
Oct 21, 2018
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology
Oct 08, 2018
Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care
Jun 21, 2018
Taiho Oncology and Servier Present Data on LONSURF® (trifluridine and tipiracil) at ESMO 20th World Congress on Gastrointestinal Cancer 2018
May 16, 2018
Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
May 09, 2018
Taiho Oncology Announces Positive Topline Results from Pivotal Phase 3 Trial of LONSURF® (trifluridine/tipiracil) in Metastatic Gastric Cancer
Apr 20, 2018
Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Apr 04, 2018
Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint
Dec 08, 2017
Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer
Oct 16, 2017
Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis
Sep 10, 2017
Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
  •  
  • Page 1
  • ››

Latest News

Jul 7, 2025

United Energy LNG and Power LNG Announce Merger to Establish an Advanced Scalable Small-Scale LNG Platform

Jul 7, 2025

Osmose Welcomes New CFO Harsha Tank to Executive Leadership Team

Jul 7, 2025

American Vanguard Announces Voting Results of 2025 Annual Meeting of Stockholders

Jul 7, 2025

White Oak Commercial Finance Agents $550 Million ABL Facility for Wilbur-Ellis Holdings

Jul 7, 2025

Ingevity releases 2024 sustainability report, highlights product innovation and technologies for a...

Jul 7, 2025

One Rock Capital Partners Raises $3.97 Billion for Fund IV, Emerald Fund and Related Vehicles

Jul 7, 2025

Element Solutions Increases Second Quarter and Full Year Outlook

Jul 7, 2025

Allegion Acquires Access Control Software Provider Gatewise

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia